WuXi is pleased to announce that STA, our small molecule API process R&D and manufacturing business unit, has completed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration with no Form 483 issued.  This is an important milestone for WuXi in our commitment of quality and reliability to our customers. This inspection outcome confirms STA’s capabilities in helping the clients move their new chemical entities through clinical development stages and eventually to commercial launch in the global market. Press Release: WuXi Manufacturing Facility Passes FDA Inspection.

Related Links:

WuXi Receives Janssen R&D Suppliers Award

WuXi Manufacturing Subsidiary STA Receives Quality CMO Award